Takeda's Zasocitinib Beats Sotyktu in Phase 3 Trial | Pharma and Biotech Daily

About this episode

Takeda's Zasocitinib outperforms Sotyktu in a Phase 3 trial for plaque psoriasis.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of remarkable updates that highlight the dynamic evolution of drug development, regulatory landscapes, and industry strategies. Takeda has made waves with its TYK2 inhibitor, Zasocitinib, which recently outperformed Bristol Myers Squibb's Sotyktu in a pivotal Phase 3 trial for plaque psoriasis. This trial is particularly notewo...

People in this episode

Host: Pharma and BioTech News

Topics covered

• drug development
• clinical trials
• pharmaceutical news
• biotech updates
• regulatory landscapes

Keywords

• Takeda
• Zasocitinib
• Sotyktu
• Phase 3 trial
• plaque psoriasis
• biotech
• pharmaceutical

Mentioned in this episode

Organizations: Takeda, Bristol Myers Squibb

Products: Zasocitinib, Sotyktu

More episodes of Pharma and BioTech Daily

• Pfizer CEO Rethinks Germany Investments Amid Reform Concerns | Pharma and Biotech Daily · June 11, 2026 · 5 min
• Merck & Gilead's HIV Pill Breakthrough: Phase 3 Success! | Pharma and Biotech Daily · June 10, 2026 · 5 min
• Eli Lilly's Retatrutide Breakthrough: 30.3% Weight Loss Success | Pharma and Biotech Daily · June 9, 2026 · 5 min
• Pfizer & Chai AI Breakthrough: $1.675B Gilead Deal | Pharma and Biotech Daily · June 8, 2026 · 5 min
• Eli Lilly & Boehringer Cut $1B+ Investments in Germany | Pharma and Biotech Daily · June 5, 2026 · 5 min
• Legend Biotech's CAR T-Cell Breakthrough: 100% Response Rate | Pharma and Biotech Daily · June 4, 2026 · 6 min